GlassScriptPhysician profile
Sreekanth Donepudi
NPI 1457526535
$2,090.20
in general payments reported to CMS, 2019-2025
26 companies · $21.46 in 2025
The $21.46 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $248 · 2021: $58.90 · 2022: $191 · 2023: $254 · 2024: $41.08 · 2025: $21.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.81 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $260.88 | 2019-2023 | Tukysa, Adcetris |
| Celgene Corporation | $225.25 | 2019-2023 | Pomalyst |
| Genentech USA, INC. | $195.31 | 2019-2020 | |
| Amgen INC. | $164.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $155.68 | 2019-2022 | |
| Incyte Corporation | $149.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.36 | 2023-2024 | Enhertu |
| Janssen Biotech, INC. | $108.84 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $106.25 | 2019-2021 | |
| Daiichi Sankyo INC. | $98.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $91.13 | 2019-2025 | Keytruda |
| Pfizer INC. | $61.88 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $40.12 | 2019-2020 | |
| Genentech, INC. | $39.95 | 2019 | |
| Lilly USA, LLC | $39.20 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $36.22 | 2019 | |
| Boston Scientific Corporation | $32.75 | 2019 | |
| Kyowa Kirin, INC. | $30.86 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.25 | 2023 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $23.94 | 2022 | |
| Clovis Oncology, INC. | $22.79 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.34 | 2019 | |
| Astellas Pharma US INC | $13.84 | 2020 | |
| Tactile Systems Technology INC | $12.41 | 2019 | |
| Emd Serono, INC. | $12.17 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreekanth Donepudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.